Thomas A. DePasquale is chairman, a serial entrepreneur, public company executive, and private investor with experience at successful startups and public companies. He advocates lower investment in drug development and focuses on innovation as a path to reducing health care.
The Cerium team has worked together for over a decade developing and commercializing medicines for rare diseases. It has an extensive network and long-standing relationships in the rare disease community.
Dr. Corey Cavanaugh is board certified in nephrology and internal medicine and specializes in glomerular diseases as a clinician, researcher, and educator at the Cleveland Clinic in Cleveland, Ohio.
Cerium Pharmaceuticals focuses on developing the first approved drug for primary membranous nephropathy (PMN), a rare kidney disease. It cites about 75,000 PMN patients in the US and 3,000 new diagnoses per year.
